Indole-3-Carbinol (I3C)
A compound from cruciferous vegetables that measurably shifts estrogen metabolite ratios. Whether that shift produces any clinical benefit is still unresolved, and the trials in precancerous lesions are small and inconsistent.
Evidence last reviewed: August 2026
What the science says
- Estrogen metabolite ratio Limited evidence
A randomized, double-blind, placebo-controlled crossover trial of an I3C-containing formula in premenopausal women reported a change in the 2-hydroxyestrone to 16α-hydroxyestrone ratio. This is a biomarker, and its link to disease outcomes has not been established.
- Cervical and vulvar precancerous lesions Limited evidence
A small placebo-controlled trial in cervical intraepithelial neoplasia reported regression with I3C in about half of treated women, but a later randomized phase II trial in vulvar intraepithelial neoplasia found no significant advantage over placebo. Both trials enrolled a few dozen participants.
Dosage & safety
Scientific references
- Placebo-controlled trial of indole-3-carbinol in the treatment of CIN
- A randomized phase II trial of indole-3-carbinol in the treatment of vulvar intraepithelial neoplasia
- A randomized, double-blind, placebo-controlled, cross-over trial to evaluate the effect of EstroSense(®) on 2-hydroxyestrone:16α-hydroxyestrone ratio in premenopausal women
Where to buy
Referral link — this site may earn a commission on purchases.
Related in Women's health
- Folic Acid (Vitamin B9) Strong evidence
- Inositol (Myo-Inositol) Moderate evidence
- Strontium Limited evidence
- Soy Isoflavones Moderate evidence
- Ipriflavone Limited evidence
- Evening Primrose Oil Limited evidence